###begin article-title 0
###xml 114 122 <span type="species:ncbi:9606">patients</span>
Selective endothelin A-receptor blockade attenuates coronary microvascular dysfunction after coronary stenting in patients with type 2 diabetes
###end article-title 0
###begin title 1
Background:
###end title 1
###begin p 2
Endothelin-1 may be involved in the development of diabetic microangiopathy. We studied the effect of endothelin-1 blockade on myocardial microcirculation during coronary stenting.
###end p 2
###begin title 3
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and methods:
###end title 3
###begin p 4
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients with type 2 diabetes and stable coronary artery disease undergoing elective percutaneous coronary intervention (PCI) were randomized to bolus dose of 500 mg bosentan (n = 4), a dual endothelin receptor blocker, or intracoronary administration of 0.03 mmol BQ123 (n = 6), a selective endothelin A-receptor blocker, or placebo (n = 5), respectively. Coronary flow reserve (CFR) was measured immediately post-PCI. CFR was also measured in five nondiabetic controls post-coronary stenting.
###end p 4
###begin title 5
Results:
###end title 5
###begin p 6
###xml 35 36 35 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 269 270 261 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 444 445 432 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 195 203 <span type="species:ncbi:9606">Patients</span>
###xml 324 332 <span type="species:ncbi:9606">patients</span>
###xml 377 385 <span type="species:ncbi:9606">patients</span>
Patients in the placebo group had (P < 0.05) lower values of CFR (2.3 +/- 1.2) as compared to those who received endothelin blockade (n = 10; 3.1 +/- 0.7) and nondiabetic controls (4.9 +/- 2.3). Patients who received BQ123 showed significantly higher CFR (3.3 +/- 0.5; P < 0.05) as compared to those on placebo. Nondiabetic patients had significantly higher CFR as compared to patients with diabetes (4.9 +/- 2.3 and 2.8 +/- 1.0, respectively; P < 0.05).
###end p 6
###begin title 7
Conclusion:
###end title 7
###begin p 8
###xml 74 82 <span type="species:ncbi:9606">patients</span>
###xml 310 318 <span type="species:ncbi:9606">patients</span>
Coronary microvascular dysfunction is present during coronary stenting in patients with type 2 diabetes and may be reversed by selective endothelin A-receptor blockade. Targeting endothelin system may be of importance in protecting the myocardium against ischemic events during elective PCI in type 2 diabetic patients.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 236 237 236 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1-vhrm-5-893">1</xref>
###xml 238 239 238 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2-vhrm-5-893">2</xref>
###xml 540 541 540 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3-vhrm-5-893">3</xref>
###xml 581 582 581 582 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sub>
###xml 677 678 677 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4-vhrm-5-893">4</xref>
###xml 679 680 679 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5-vhrm-5-893">5</xref>
Endothelial dysfunction, characterized by an imbalance between endothelium-derived vasodilator and vasoconstrictor substances, plays an important role in the pathogenesis of vascular complications in diabetes, including microangiopathy.1,2 One important feature of endothelial dysfunction is an increased production and biological activity of the potent vasoconstrictor and proinflammatory peptide endothelin-1 (ET-1), which has been suggested to be involved in the development of cardiovascular disease, including diabetic microangiopathy.3 Activation of endothelin A-receptor (ETA) contributes to coronary constrictor tone and peripheral and coronary endothelial dysfunction.4,5
###end p 10
###begin p 11
###xml 67 68 67 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6-vhrm-5-893">6</xref>
###xml 69 70 69 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7-vhrm-5-893">7</xref>
###xml 83 84 83 84 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sub>
###xml 220 221 220 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8-vhrm-5-893">8</xref>
###xml 283 284 283 284 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sub>
###xml 37 45 <span type="species:ncbi:9606">patients</span>
###xml 170 178 <span type="species:ncbi:9606">patients</span>
###xml 378 386 <span type="species:ncbi:9606">patients</span>
Elevated levels of ET-1 are found in patients with type 2 diabetes.6,7 Selective ETA receptor blockade by BQ123 markedly increases the nutritive skin microcirculation in patients with type 2 diabetes and microangiopathy.8 These results suggest that ET-1, through activation of the ETA receptor, is of importance for the regulation of the peripheral microcirculation in diabetic patients with microangiopathy.
###end p 11
###begin p 12
###xml 171 172 171 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9-vhrm-5-893">9</xref>
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10-vhrm-5-893">10</xref>
###xml 488 490 488 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11-vhrm-5-893">11</xref>
###xml 491 493 491 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13-vhrm-5-893">13</xref>
###xml 595 596 595 596 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sub>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
###xml 419 427 <span type="species:ncbi:9606">patients</span>
###xml 631 639 <span type="species:ncbi:9606">patients</span>
An impaired coronary flow reserve (CFR) has been demonstrated in patients with metabolic syndrome and type 2 diabetes without clinical evidence of coronary artery disease.9,10 Percutaneous coronary intervention (PCI) with balloon angioplasty and coronary stenting causes arterial injury, resulting in platelet activation, vasoconstrictor release and abnormalities in endothelial-dependent vasodilatation, which in some patients might lead to adverse effects on the microvascular function.11-13 The aim of the present study was to evaluate CFR and to determine the effect of dual and selective ETA blockade, respectively, on CFR in patients with type 2 diabetes undergoing elective coronary stenting.
###end p 12
###begin title 13
Material and methods
###end title 13
###begin title 14
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient population
###end title 14
###begin p 15
###xml 7 15 <span type="species:ncbi:9606">patients</span>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
###xml 128 136 <span type="species:ncbi:9606">patients</span>
###xml 429 437 <span type="species:ncbi:9606">patients</span>
###xml 475 480 <span type="species:ncbi:9606">human</span>
Twenty patients, 15 with type 2 diabetes and five nondiabetic patients undergoing nonacute PCI were eligible for the study. The patients were admitted for elective PCI because of stable one vessel coronary artery disease. Exclusion criteria included previous myocardial infarction in the territory of the study artery, congestive heart failure and previous coronary artery bypass grafting. Informed consent was obtained from all patients. The study was approved by the local human ethics committee of the Karolinska Institute.
###end p 15
###begin title 16
Methods
###end title 16
###begin p 17
###xml 485 488 485 486 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#174;</sup>
###xml 559 560 557 558 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sub>
###xml 1147 1149 1145 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14-vhrm-5-893">14</xref>
###xml 1150 1152 1148 1150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15-vhrm-5-893">15</xref>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 66 74 <span type="species:ncbi:9606">Patients</span>
###xml 171 179 <span type="species:ncbi:9606">patients</span>
###xml 289 297 <span type="species:ncbi:9606">Patients</span>
###xml 325 331 <span type="species:ncbi:13443">coffee</span>
###xml 366 374 <span type="species:ncbi:9606">Patients</span>
###xml 667 675 <span type="species:ncbi:9606">Patients</span>
###xml 1221 1229 <span type="species:ncbi:9606">patients</span>
All patients were treated with aspirin, statins and betablockers. Patients with diabetes and three controls were treated with angiotensin-converting enzyme inhibitor. All patients received a loading dose of 600 mg clopidogrel 12 hours prior to PCI, followed by 75 mg on the procedure day. Patients were asked to refrain from coffee for at least 12 hours before PCI. Patients with diabetes were randomized to receive either dual ET-1 receptor blocker bosentan (Group A; n = 4) (Tracleer(R), Actelion Pharmaceuticals, Allschwil, Switzerland) or the selective ETA blocker BQ123 (Group B; n = 6) (Clinalfa, Laufelfingen, Switzerland) or placebo tablets (Group C; n = 5). Patients in Group A received a bolus dose of 500 mg bosentan three hours prior to PCI. In Group B, a total dose of 0.03 mmol (9 mL) BQ123 was injected intracoronary during the PCI procedure; 0.01 mmol before inflation of the predilation balloon, 0.01 mmol after balloon deflation, and 0.01 mmol after stenting. Group C received placebo tablets three hours prior to PCI. The doses of BQ123 and bosentan, respectively, were based on previous studies on peripheral vascular function.14,15 CFR and fractional flow reserve (FFR) were measured post-PCI in all patients including five nondiabetic controls.
###end p 17
###begin title 18
PCI with coronary stenting
###end title 18
###begin p 19
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 150 158 <span type="species:ncbi:9606">patients</span>
###xml 436 444 <span type="species:ncbi:9606">patients</span>
###xml 512 520 <span type="species:ncbi:9606">patients</span>
All patients underwent one vessel PCI with coronary stenting with either drug-eluting stents or bare metal stents via 6-French guiding catheters. All patients received the low-molecular-weight heparin enoxaparin (0.5 mg per kg body weight) immediately after insertion of the arterial sheet. Intraarterial blood pressure and electrocardiogram were continuously monitored during PCI. Intracoronary injections of nitrate were given to all patients before stenting and before measurement of CFR and FFR. None of the patients were treated with glycoprotein receptor blocker or bivalirudin.
###end p 19
###begin title 20
CFR and FFR measurements
###end title 20
###begin p 21
###xml 1097 1099 1091 1093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16-vhrm-5-893">16</xref>
###xml 1303 1305 1297 1299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17-vhrm-5-893">17</xref>
At the end of the PCI procedure, a 0.014-inch fiberoptic pressure-temperature sensor-tipped guide wire (Pressure Wire Sensor 5; Radi Medical Systems, Uppsala, Sweden) was initially held in the proximal part of the target vessel for equalizing of the pressure between coronary artery and intraaortic pressure, and then advanced through the guiding catheter and positioned distal to the PCI-treated segment for simultaneous measurements of CFR and FFR, respectively. Besides a pressure sensor, this wire has a microsensor at 3 cm from the floppy tip, which enables simultaneous recording of high fidelity temperature with an accuracy of 0.02 degreesC. The shaft of the wire, acting as an additional electric resistance, can be used as a second thermistor which records the input signal at the coronary ostium of any fluid injection with a temperature different from blood. Intravenous adenosine was used as hyperemic agent. The mean transit time at rest and during hyperemia were recorded after rapid injection of 3 mL of room temperature saline through the guiding catheter as previously described.16 The hyperemic and resting mean transit times were measured three times and averaged. Thermodilution-derived CFR was calculated as the resting mean transit time divided by the hyperemic mean transit time.17
###end p 21
###begin title 22
Blood analysis
###end title 22
###begin p 23
###xml 234 236 234 236 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1c</sub>
Venous blood samples were obtained 12-16 hours after PCI for analysis of cardiac enzymes (CK-MB and troponin I). Blood lipids including low-density lipoprotein (LDL) and high-density lipoprotein (HDL), and glycosylated hemoglobin (HbA1c) were assessed at least four weeks prior to PCI according to local laboratory routines.
###end p 23
###begin title 24
Statistical analysis
###end title 24
###begin p 25
###xml 189 190 187 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Data are shown as means +/- standard error (SE). The nonparametric Mann-Whitney test was used to analyze the differences between the groups regarding CFR. A two-tailed probability value of P < 0.05 was considered significant.
###end p 25
###begin title 26
Results
###end title 26
###begin p 27
###xml 59 66 59 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1-vhrm-5-893">Table 1</xref>
###xml 136 138 136 138 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1c</sub>
###xml 33 41 <span type="species:ncbi:9606">patients</span>
###xml 239 247 <span type="species:ncbi:9606">patients</span>
###xml 284 292 <span type="species:ncbi:9606">patients</span>
###xml 387 395 <span type="species:ncbi:9606">patients</span>
The basal characteristics of the patients are presented in Table 1. There were no significant differences in age, diabetes duration, HbA1c, pre-PCI blood pressure or blood lipids between the groups. The PCI procedure was successful in all patients. Drug-eluted stents were used in 10 patients with diabetes and in two nondiabetic controls. Bare metal stents (BMS) were used in remaining patients. There were no angiographic signs of PCI-related complications in the coronary vessels such as dissection or formation of thrombosis with or without peripheral embolization.
###end p 27
###begin p 28
###xml 255 263 255 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1-vhrm-5-893">Figure 1</xref>
###xml 265 272 265 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2-vhrm-5-893">Table 2</xref>
###xml 491 498 491 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2-vhrm-5-893">Table 2</xref>
###xml 77 85 <span type="species:ncbi:9606">patients</span>
###xml 116 124 <span type="species:ncbi:9606">patients</span>
###xml 330 338 <span type="species:ncbi:9606">patients</span>
###xml 405 413 <span type="species:ncbi:9606">Patients</span>
Post-PCI CFR was significantly higher in nondiabetic controls as compared to patients with diabetes, while diabetic patients who received placebo (group C) showed significantly lower CFR compared to those who received endothelin blocker (Groups A and B) (Figure 1; Table 2). However, there was a tendency to lower CFR in diabetic patients who received endothelin blocker compared to nondiabetic controls. Patients who received bosentan showed lower CFR values than those who received BQ123 (Table 2).
###end p 28
###begin p 29
###xml 183 190 183 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2-vhrm-5-893">Table 2</xref>
###xml 771 778 771 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2-vhrm-5-893">Table 2</xref>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
###xml 240 248 <span type="species:ncbi:9606">patients</span>
###xml 318 326 <span type="species:ncbi:9606">patients</span>
###xml 376 384 <span type="species:ncbi:9606">patients</span>
###xml 627 635 <span type="species:ncbi:9606">patients</span>
###xml 637 645 <span type="species:ncbi:9606">Patients</span>
Post-PCI FFR were within normal range in all patients indicating successful treatment of the epicardial stenosis, and there were no significant differences in FFR between the groups (Table 2). CK-MB and troponin-I levels were normal in all patients prior to PCI and there were no significant increases post-PCI in any patients. A resting electrocardiogram was obtained in all patients 12-16 hours post-PCI and did not show any new changes indicative of myocardial ischemia or myocardial infarction following the PCI procedure. Intraarterial systolic blood pressure values were lower post-PCI compared to pre-PCI in most of the patients. Patients in the bosentan group and nondiabetic controls had higher blood pressure pre- and post-PCI compared to the two other groups (Table 2).
###end p 29
###begin title 30
Discussion
###end title 30
###begin p 31
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18-vhrm-5-893">18</xref>
###xml 269 270 269 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8-vhrm-5-893">8</xref>
###xml 412 413 412 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9-vhrm-5-893">9</xref>
###xml 414 416 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10-vhrm-5-893">10</xref>
###xml 897 899 897 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19-vhrm-5-893">19</xref>
###xml 246 254 <span type="species:ncbi:9606">patients</span>
###xml 366 374 <span type="species:ncbi:9606">patients</span>
###xml 471 479 <span type="species:ncbi:9606">patients</span>
###xml 850 858 <span type="species:ncbi:9606">patients</span>
Diabetic microangiopathy is characterized by reduced microvascular reactivity and impaired nutritive capillary circulation.18 ET-1 through increased endothelial dysfunction has been suggested to contribute to impaired microvascular reactivity in patients with diabetes.8 There is increasing evidence of the presence of disturbed myocardial microvascular function in patients with diabetes and metabolic syndrome.9,10 Disturbed microvascular function in the myocardium of patients with diabetes may play an important role in the pathogenesis of systolic and diastolic myocardial dysfunction in absence of epicardial coronary artery disease. As in peripheral microcirculation, an impaired coronary microvascular function is seen during ischemic and/or mechanical stress, eg, PCI, which is suggested to partly explain poor long-term outcome in diabetic patients undergoing coronary revascularization.19
###end p 31
###begin p 32
###xml 404 405 404 405 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sub>
###xml 67 75 <span type="species:ncbi:9606">patients</span>
###xml 352 360 <span type="species:ncbi:9606">patients</span>
The present study was undertaken to explore the hypothesis that in patients with type 2 diabetes, myocardial microvascular function is impaired during percutaneous coronary intervention, and that it can be restored by endothelin-receptor blockade. The results show that coronary microvascular dysfunction is present after PCI with coronary stenting in patients with type 2 diabetes, and that selective ETA blockade attenuate microvascular dysfunction in the myocardium.
###end p 32
###begin p 33
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20-vhrm-5-893">20</xref>
###xml 429 431 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23-vhrm-5-893">23</xref>
###xml 643 644 643 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6-vhrm-5-893">6</xref>
###xml 645 646 645 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7-vhrm-5-893">7</xref>
###xml 647 649 647 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24-vhrm-5-893">24</xref>
###xml 759 761 759 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25-vhrm-5-893">25</xref>
###xml 935 937 935 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26-vhrm-5-893">26</xref>
###xml 938 940 938 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27-vhrm-5-893">27</xref>
###xml 613 621 <span type="species:ncbi:9606">patients</span>
In type 2 diabetes, there is a complex interaction between impaired insulin sensitivity, vascular endothelial dysfunction, and hypertension, which seems to play an important role in the development of functional disturbances in the microcirculation. Impaired insulin sensitivity is associated with a modif ication of arterial resistance, increased microvascular resistance and macro- and microvascular endothelial dysfunction.20-23 ET-1 is one of the most potent vasoconstrictors described and has been suggested to contribute to vascular endothelial dysfunction in diabetes. Elevated levels of ET-1 are found in patients with type 2 diabetes,6,7,24 and ET-1-induced reduction in insulin sensitivity may take part in the development of the metabolic syndrome.25 In diabetes mellitus, a primary disturbance in ET-1 production from vascular endothelium exists as an early phenomenon rather than a result of advanced stage of the disease.26,27
###end p 33
###begin p 34
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28-vhrm-5-893">28</xref>
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30-vhrm-5-893">30</xref>
###xml 280 281 280 281 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sub>
###xml 288 289 288 289 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</sub>
###xml 365 366 365 366 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sub>
###xml 373 374 373 374 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</sub>
###xml 420 421 420 421 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</sub>
###xml 422 424 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31-vhrm-5-893">31</xref>
###xml 451 452 451 452 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sub>
###xml 504 505 504 505 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</sub>
###xml 602 604 602 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32-vhrm-5-893">32</xref>
###xml 605 607 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33-vhrm-5-893">33</xref>
###xml 610 611 610 611 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sub>
###xml 725 726 725 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4-vhrm-5-893">4</xref>
###xml 727 728 727 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5-vhrm-5-893">5</xref>
Furthermore, ET-1 may contribute to the development of endothelial dysfunction, and consequently insulin resistance, by increasing the production of reactive oxygen species, mainly superoxide anion, in the vasculature.28-30 Two receptor subtypes, endothelin A- and B-receptors (ETA and ETB), mediate the effects of ET-1. Vascular smooth muscle cells express both ETA and ETB, while endothelial cells express primarily ETB.31 On smooth muscle cells, ETA mediates vasoconstriction and mitogenesis, while ETB receptor has a dual function and has been shown to cause both vasoconstriction and vasodilation.32,33 ETA receptor activation contributes to coronary constrictor tone and peripheral and coronary endothelial dysfunction.4,5
###end p 34
###begin p 35
###xml 479 481 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34-vhrm-5-893">34</xref>
###xml 482 484 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37-vhrm-5-893">37</xref>
###xml 688 690 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20-vhrm-5-893">20</xref>
###xml 691 693 691 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38-vhrm-5-893">38</xref>
###xml 979 981 979 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19-vhrm-5-893">19</xref>
###xml 982 984 982 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20-vhrm-5-893">20</xref>
###xml 3 11 <span type="species:ncbi:9606">patients</span>
###xml 350 358 <span type="species:ncbi:9606">patients</span>
###xml 485 492 <span type="species:ncbi:9606">Patient</span>
###xml 731 739 <span type="species:ncbi:9606">patients</span>
###xml 822 830 <span type="species:ncbi:9606">patients</span>
###xml 956 964 <span type="species:ncbi:9606">patients</span>
###xml 1110 1118 <span type="species:ncbi:9606">patients</span>
###xml 1165 1173 <span type="species:ncbi:9606">patients</span>
###xml 1215 1223 <span type="species:ncbi:9606">patients</span>
###xml 1488 1496 <span type="species:ncbi:9606">patients</span>
In patients with acute myocardial infarction, microvascular function in the myocardium measured by CFR is impaired due to several complex factors such as distal embolization, activation of vasoactive peptides, eg, ET-1, and reperfusion injury through several plausible pathways, eg, protein kinase C activation. Assessment of post-reperfusion CFR in patients with acute myocardial infarction seems to predict left ventricle function recovery and future short-term cardiac events.34-37 Patient with diabetes have poor long term outcome after coronary artery stenting partly because of being more prone to distal embolization and exaggerated myocardial microvascular dysfunction during PCI.20,38 In the study by Kini and colleagues, patients with diabetes showed significantly lower CFR after PCI as compared to nondiabetic patients despite treatment with the glycoprotein receptor inhibitor abciximab suggesting more pronounced microvascular dysfunction in patients with diabetes.19,20 In the present study, impaired CFR post-PCI was partly reversed by intracoronary injection of selective ETA blocker BQ123 in patients with diabetes. However, CFR remained lower in patients with diabetes as compared to nondiabetic patients despite dual and selective endothelin receptor blockade, respectively. These results indicate that beside ET-1, other neurohumoral and/or inflammatory mechanisms may be involved in the pathogenesis of microvascular dysfunction during coronary stenting in diabetic patients.
###end p 35
###begin p 36
###xml 319 320 319 320 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sub>
###xml 327 328 327 328 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</sub>
###xml 364 365 364 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5-vhrm-5-893">5</xref>
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39-vhrm-5-893">39</xref>
###xml 651 653 651 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15-vhrm-5-893">15</xref>
###xml 105 113 <span type="species:ncbi:9606">patients</span>
CFR was somehow lower in bosentan group as compared to BQ123 group, and only slightly higher compared to patients in placebo group. The difference in efficacy between dual and selective endothelin receptor blockade with regard to reversal of myocardial microvascular dysfunction may be due to the different action of ETA and ETB receptors in various vascular beds.5,39 In the study by Halcox and colleagues, bosentan, in opposite to BQ123, did not produce microvascular coronary vasodilation despite epicardial vasodilation. A significant effect of 500 mg bosentan on peripheral vascular endothelial function has been demonstrated in previous studies,15 however, a low local myocardial concentration of the drug may also partly explain why bosentan did not produce the same response as intracoronary injected BQ123.
###end p 36
###begin p 37
###xml 58 60 58 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b40-vhrm-5-893">40</xref>
###xml 61 63 61 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41-vhrm-5-893">41</xref>
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42-vhrm-5-893">42</xref>
###xml 577 578 577 578 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sub>
###xml 152 160 <span type="species:ncbi:9606">patients</span>
###xml 219 227 <span type="species:ncbi:9606">patients</span>
###xml 364 372 <span type="species:ncbi:9606">patients</span>
###xml 507 515 <span type="species:ncbi:9606">patients</span>
Coronary flow reserve is impaired in arterial hypertension40,41 and independently associated with myocardial diastolic function, seen early in diabetic patients.42 Blood pressure prior to PCI was well controlled in all patients prior to PCI, however, intraarterial measured systolic and diastolic blood pressures at baseline was higher in nondiabetic controls and patients in BQ123 group, and remained higher in these two groups at the end of PCI procedure. Despite higher blood pressure, CFR was higher in patients receiving BQ123, indicating a positive effect of selective ETA blockade on myocardial microcirculation.
###end p 37
###begin p 38
###xml 274 275 274 275 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sub>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
###xml 357 365 <span type="species:ncbi:9606">patients</span>
There are limitations with the present study. Small numbers of patients are included in each group in this pilot-study. However, a significant effect on CFR seems to have been produced by intracoronary BQ123 in such a limited study population indicating that ET-1 through ETA activation is important in regulation of myocardial microcirculation in diabetic patients. Another limitation is that serum ET-1 levels were not analyzed. However, serum levels of ET-1 are not a reliable measure of its biological activity in the vasculature, or expression of ET-1 receptors. Finally, there is no matched placebo group against BQ123 group, but the probability that intermittent intracoronary injection with physiological saline of a total volume of 9 mL would influence CFR is low.
###end p 38
###begin p 39
###xml 70 71 70 71 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sub>
###xml 163 171 <span type="species:ncbi:9606">patients</span>
In conclusion, the results of the present study show that selective ETA receptor blockade attenuates coronary microvascular dysfunction after coronary stenting in patients with type 2 diabetes. The results need to be confirmed in a larger double-blind placebo-controlled study.
###end p 39
###begin p 40
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Disclosures</bold>
Disclosures
###end p 40
###begin p 41
The authors report no conflicts of interest in this work.
###end p 41
###begin title 42
References
###end title 42
###begin article-title 43
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I
###end article-title 43
###begin article-title 44
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II
###end article-title 44
###begin article-title 45
The importance of endothelin-1 for microvascular dysfunction in diabetes
###end article-title 45
###begin article-title 46
###xml 98 106 <span type="species:ncbi:9606">patients</span>
Endogenous endothelin maintains coronary artery tone by endothelin type A receptor stimulation in patients undergoing coronary arteriography
###end article-title 46
###begin article-title 47
Coronary vasodilation and improvement in endothelial dysfunction with endothelin ET(A) receptor blockade
###end article-title 47
###begin article-title 48
###xml 30 38 <span type="species:ncbi:9606">patients</span>
Elevated plasma endothelin in patients with diabetes mellitus
###end article-title 48
###begin article-title 49
###xml 77 82 <span type="species:ncbi:9606">human</span>
Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes
###end article-title 49
###begin article-title 50
###xml 80 88 <span type="species:ncbi:9606">patients</span>
Endothelin-A receptor blockade improves nutritive skin capillary circulation in patients with type 2 diabetes and albuminuria
###end article-title 50
###begin article-title 51
###xml 34 42 <span type="species:ncbi:9606">patients</span>
Impaired coronary flow reserve in patients with metabolic syndrome
###end article-title 51
###begin article-title 52
Effects of reduced coronary flow reserve on left ventricular function in type 2 diabetes
###end article-title 52
###begin article-title 53
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Expression of polymorphonuclear leukocyte adhesion molecules and its clinical significance in patients treated with percutaneous transluminal coronary angioplasty
###end article-title 53
###begin article-title 54
###xml 12 17 <span type="species:ncbi:9606">human</span>
Response of human coronary arteries to acetylcholine after injury by coronary angioplasty
###end article-title 54
###begin article-title 55
Long-term endothelial dysfunction after coronary artery stenting
###end article-title 55
###begin article-title 56
###xml 73 81 <span type="species:ncbi:9606">patients</span>
Improved peripheral perfusion during endothelin - a receptor blockade in patients with type 2 diabetes and critical limb ischemia
###end article-title 56
###begin article-title 57
###xml 120 126 <span type="species:ncbi:9606">humans</span>
The endothelin-1 receptor antagonist bosentan protects against ischaemia/reperfusion-induced endothelial dysfunction in humans
###end article-title 57
###begin article-title 58
Coronary thermodilution ta asssess flow reserve. Experimental validation
###end article-title 58
###begin article-title 59
###xml 62 68 <span type="species:ncbi:9606">humans</span>
Coronary thermodilution to assess flow reserve: Validation in humans
###end article-title 59
###begin article-title 60
Possible pathophysiological mechanisms for diabetic angiopathy in type 2 diabetes
###end article-title 60
###begin article-title 61
###xml 67 75 <span type="species:ncbi:9606">patients</span>
Comparison of coronary flow reserve and fractional flow reserve in patients with versus without diabetes mellitus and having elective percutaneous coronary intervention and abciximab therapy (from the PREDICT Trial)
###end article-title 61
###begin article-title 62
Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes
###end article-title 62
###begin article-title 63
###xml 22 30 <span type="species:ncbi:9606">patients</span>
Capillary pressure in patients with NIDDM
###end article-title 63
###begin article-title 64
###xml 155 163 <span type="species:ncbi:9606">patients</span>
Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients
###end article-title 64
###begin article-title 65
Reduced microvascular hyperaemia in subjects at risk of developing type 2 (non-insulin-dependent) diabetes mellitus
###end article-title 65
###begin article-title 66
Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade
###end article-title 66
###begin article-title 67
###xml 60 61 60 61 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sub>
###xml 68 69 68 69 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</sub>
###xml 91 97 <span type="species:ncbi:9606">humans</span>
Insulin sensitivity and big ET-1 conversion to ET-1 after ETA- or ETB-receptor blockade in humans
###end article-title 67
###begin article-title 68
###xml 34 42 <span type="species:ncbi:9606">patients</span>
Plasma endothelin levels in NIDDM patients with macroangiopathy
###end article-title 68
###begin article-title 69
Relevance of the vascular effects of insulin in the rationale of its therapeutical use
###end article-title 69
###begin article-title 70
Role for endothelin-1-induced superoxide and peroxynitrite production in rebound pulmonary hypertension associated with inhaled nitric oxide therapy
###end article-title 70
###begin article-title 71
Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension
###end article-title 71
###begin article-title 72
Quercetin inhibits vascular superoxide production induced by endothelin-1: Role of NADPH oxidase, uncoupled eNOS and PKC
###end article-title 72
###begin article-title 73
###xml 73 78 <span type="species:ncbi:9606">human</span>
Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium
###end article-title 73
###begin article-title 74
Molecular characterization of endothelin receptors
###end article-title 74
###begin article-title 75
###xml 66 71 <span type="species:ncbi:9606">human</span>
Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels
###end article-title 75
###begin article-title 76
Impaired perfusion after myocardial infarction is due to reperfusion-induced deltaPKC-mediated myocardial damage
###end article-title 76
###begin article-title 77
Non-invasive coronary flow reserve after successful primary angioplasty for acute anterior myocardial infarction is an independent predictor of left ventricular recovery and in-hospital cardiac events
###end article-title 77
###begin article-title 78
###xml 158 166 <span type="species:ncbi:9606">patients</span>
Coronary microvascular resistance index immediately after primary percutaneous coronary intervention as a predictor of the transmural extent of infarction in patients with ST-segment elevation anterior acute myocardial infarction
###end article-title 78
###begin article-title 79
Coronary flow velocity reserve after percutaneous interventions is predictive of periprocedural outcome
###end article-title 79
###begin article-title 80
Abnormal coronary flow velocity reserve after coronary intervention is associated with cardiac marker elevation
###end article-title 80
###begin article-title 81
###xml 25 30 <span type="species:ncbi:9606">human</span>
Endogenous endothelin in human coronary vascular function: Differential contribution of endothelin receptor types A and B
###end article-title 81
###begin article-title 82
Independent association of coronary flow reserve with left ventricular relaxation and filling pressure in arterial hypertension
###end article-title 82
###begin article-title 83
Coronary flow reserve and myocardial diastolic dysfunction in arterial hypertension
###end article-title 83
###begin article-title 84
A randomized trial of the impact of strict glycaemic control on myocardial diastolic function and perfusion reserve: a report from the DADD (Diabetes mellitus And Diastolic Dysfunction) study
###end article-title 84
###begin p 85
###xml 57 65 <span type="species:ncbi:9606">patients</span>
###xml 115 123 <span type="species:ncbi:9606">Patients</span>
Coronary flow reserve (CFR) post-coronary stenting in 20 patients; 15 with diabetes and five nondiabetic controls. Patients with diabetes were randomized to bosentan (group A; n = 4), BQ123 (group B; n = 6) or placebo (group c; n = 5).
###end p 85
###begin p 86
###xml 31 39 <span type="species:ncbi:9606">patients</span>
###xml 119 127 <span type="species:ncbi:9606">Patients</span>
Baseline characteristics of 20 patients, 15 with diabetes and five nondiabetic controls, undergoing coronary stenting. Patients with diabetes were randomized to endothelin blocker or placebo
###end p 86
###begin p 87
###xml 0 6 0 6 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Notes:</bold>
###xml 155 163 <span type="species:ncbi:9606">patients</span>
###xml 218 226 <span type="species:ncbi:9606">patients</span>
###xml 278 286 <span type="species:ncbi:9606">Patients</span>
Notes: Values are means +/- SE. There were no significant differences between the groups regarding age, diabetes duration, systolic and diastolic group A: patients with diabetes who received bosentan (n = 4). group B: patients with diabetes who received BQ123 (n = 6). group c: Patients with diabetes who received placebo (n = 5).
###end p 87
###begin p 88
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviations:</bold>
###xml 18 20 18 20 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1c</sub>
Abbreviations: HbA1c, glycosylated hemoglobin; crcl, creatinine clearance; LDL, low-density lipoprotein; HDL, high-density lipoprotein; LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery; SE, standard error.
###end p 88
###begin p 89
###xml 68 76 <span type="species:ncbi:9606">patients</span>
###xml 151 159 <span type="species:ncbi:9606">Patients</span>
Post-PCI values of CFR, FFR, and intraarterial blood pressure in 15 patients with diabetes and five nondiabetic controls undergoing coronary stenting. Patients with diabetes were randomized to endothelin blocker or placebo
###end p 89
###begin p 90
###xml 0 6 0 6 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Notes:</bold>
Notes: Values are means +/- SE.
###end p 90
###begin p 91
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 24 32 <span type="species:ncbi:9606">patients</span>
P < 0.05 as compared to patients on placebo (group c).
###end p 91
###begin p 92
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 24 32 <span type="species:ncbi:9606">patients</span>
P < 0.05 as compared to patients with diabetes (n = 15).
###end p 92
###begin p 93
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviations:</bold>
Abbreviations: CFR, coronary flow reserve; FFR, fractional flow reserve; PCI, percutaneous coronary intervention; SE, standard error.
###end p 93

